Everest Medicines, a privately held biotech company, has partnered with Travere Therapeutics to bring a novel kidney disease treatment to market under a licensing agreement valued at up to $1.14 billion.
Everest Medicines, a private biotech company, has partnered with Travere Therapeutics (TVTX.O) in a significant agreement announced on Tuesday. The partnership will focus on developing and marketing a novel treatment for kidney disease, valued at up to $1.14 billion.
Related ↗A powerful earthquake measuring 7.8 magnitude hits the south of Philippines.Travere has secured licensing rights.
Travere has secured an agreement granting them sole authority to market and distribute civorebrutinib globally, except in China and select regions of East and Southeast Asia.
Read next ↗New Obesity Treatment from Boehringer-Zealand Reduces Visceral Liver Fat Effectively.Travere has licensed Everest's kidney disease treatment for a maximum value of $1.14 billion. This includes an initial payment of $112.5 million with potential additional payments up to $1.03 billion.
Travere will receive additional revenue from future sales.
A novel oral therapy, Civorebrutinib (EVER001), is currently under investigation for its potential to treat rare autoimmune kidney disorders.
Travere offers two FDA-approved treatments for kidney issues: Filspari for IgA nephropathy and focal segmental glomerulosclerosis, as well as Thiola for cystinuria.
Travere has announced its intention to assess the efficacy of this treatment across several uncommon kidney conditions.
Travelling through the body's immune system, civorebrutinib acts as a BTK inhibitor, effectively silencing B-cell signals to prevent antibody overproduction.
The company reports that patients have shown good tolerance to the medication overall.
